Oxford Biomedica PLC Logo

Oxford Biomedica PLC

A CDMO for cell & gene therapy, providing end-to-end viral vector development & manufacturing.

OXB | IL

Overview

Corporate Details

ISIN(s):
GB00BDFBVT43
LEI:
213800S1GVQNXQ15K851
Country:
United Kingdom
Address:
WINDRUSH COURT, OX4 6LT OXFORD
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Oxford Biomedica PLC (OXB) is a global, innovation-led contract development and manufacturing organization (CDMO) specializing in cell and gene therapy. As a pioneer with over 30 years of experience, the company provides end-to-end services for the development and GMP manufacturing of viral vectors, including lentivirus, adeno-associated virus (AAV), and adenovirus. OXB supports pharmaceutical and biotechnology clients, from early-stage development to commercialization, through its global network of facilities in the UK, US, and France. The company leverages proprietary technology platforms, such as its commercially approved LentiVector™ and inAAVate™ systems, to enable the delivery of life-changing therapies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-16 08:00
Director's Dealing
Director/PDMR Shareholding
English 36.9 KB
2025-10-01 08:00
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights
English 11.6 KB
2025-09-23 08:00
Earnings Release
Interim Results for 6 months ended 30 June 2025
English 732.3 KB
2025-08-22 16:36
Director's Dealing
PDMR Dealings
English 29.1 KB
2025-08-21 11:24
Major Shareholding Notification
Holding(s) in Company
English 22.2 KB
2025-08-20 08:00
Declaration of Voting Results & Voting Rights Announcements
Admission of Shares and Total Voting Rights
English 10.9 KB
2025-08-15 14:45
Director's Dealing
PDMR Dealings
English 18.8 KB
2025-08-15 08:05
Share Issue/Capital Change
Results of Placing
English 43.5 KB
2025-08-14 18:02
Share Issue/Capital Change
Proposed Placing of New Ordinary Shares
English 168.6 KB
2025-08-01 08:00
Capital/Financing Update
OXB Secures New Loan Facility with Oaktree
English 16.3 KB
2025-08-01 08:00
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights
English 10.9 KB
2025-07-28 08:00
Earnings Release
Half Year Trading Update
English 23.8 KB
2025-07-02 08:00
Board/Management Information
Director Declaration
English 9.6 KB
2025-06-23 08:00
M&A Activity
OXB completes acquisition of US subsidiary
English 12.3 KB
2025-06-17 19:00
Director's Dealing
Director/PDMR Shareholding
English 18.8 KB

Automate Your Workflow. Get a real-time feed of all Oxford Biomedica PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Oxford Biomedica PLC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Oxford Biomedica PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
NeoImmuneTech, Inc. Logo
Develops NT-I7, a T cell-amplifying immunotherapy for cancer and infectious diseases.
United States of America 950220
Newbury Pharmaceuticals AB Logo
Develops specialty prescription drugs for Scandinavia in oncology, rare diseases & neurology.
Sweden NEWBRY
New Nordic Healthbrands AB Logo
Develops and markets herbal supplements & beauty products for natural wellness consumers globally.
Sweden NNH
Newron Pharmaceuticals S.p.A. Logo
Biopharma developing novel therapies for nervous system diseases like Parkinson's and schizophrenia.
Italy NWRN
NextCell Pharma AB Logo
Develops off-the-shelf cell therapies for autoimmune diseases like type 1 diabetes.
Sweden NXTCL
NGeneBio Co., Ltd. Logo
Provides NGS-based diagnostics, software, and liquid biopsy for precision oncology and healthcare.
South Korea 354200
NIBEC CO., LTD. Logo
Biotech CDMO creating regenerative products with peptide and biomaterial technologies.
South Korea 138610
NIPPON CHEMIPHAR CO., LTD. Logo
Develops generic drugs, allergy treatments, and novel pharmaceuticals for a global market.
Japan 4539
Nippon Shinyaku Co.,Ltd. Logo
Develops pharmaceuticals and functional foods to improve healthcare and wellbeing.
Japan 4516
NKMAX Co., Ltd. Logo
Biotech firm for NK cell therapies, global research reagents, diagnostics, and supplements.
South Korea 182400

Talk to a Data Expert

Have a question? We'll get back to you promptly.